

**IOptima (Subsidiary) : First sale of the IOptiMate™ System in Belarus ; Material Sales of the LIPITEAR™ product during Q2/18**

Tel Aviv (June 24, 2018) – BioLight is pleased to announce that today, its subsidiary IOptima Ltd., ("**IOptima**")<sup>1</sup>, announced first sale of its IOptiMate™ System in Belarus to a hospital in said territory. The sale was carried out through IOptima's local distributor in Belarus, with which an exclusive distribution agreement was signed and after the recent receipt of the required regulatory certificate from the Health Ministry in Belarus.

This report is published in accordance with BioLight's policy regarding the publication of reports on each first sale of the IOptiMate™ System in a new territory.

In addition, IOptima updated BioLight that since the beginning of the second quarter of 2018, and until today, the LIPITEAR™ product<sup>2</sup> was sold, for the first time, for a total substantial amount of over NIS 450 thousand.

---

<sup>1</sup> After completing the first phase of the investment and purchase agreement with the Chinese pharmaceutical company (the "**Agreement**"), BioLight holds, via XL Vision Sciences Ltd., 57% of the issued and share capital of IOptima (approximately 55% in full dilution). For additional information regarding the Agreement, please see BioLight's report of March 29, 2018.

<sup>2</sup> The marketing, sales and distribution of the LIPITEAR™ product, certified product for marketing and sales in Europe, for the treatment of Dry eye syndrome and additional use of eye diseases, in respect of which BioLight signed non-exclusive sub-license agreements with IOptima. For more information please see section 4.5.2 of BioLight's annual report for the year 2017.